US company’s patent bid for life-saving TB therapy nixed

NewsIndia NewsUS company’s patent bid for life-saving TB therapy nixed GURGAON: The Indian Patent Office has rejected a patent application by US-based Global Alliance for TB Drug Development for BPaL, a life-saving tuberculosis therapy, citing lack of novelty and inventive step.

The decision could allow domestic drugmakers to launch cheaper generic versions in India and other high-burden countries, health experts said.Govt provides BPaL, a combination of bedaquiline, pretomanid and linezolid, free under National TB Elimination Programme.

However, treatment costs remain a challenge. The six-month all-oral regimen is shorter than older treatments and reduces patients’ compliance burden. More than 15,000 patients have begun BPaLM, which adds moxifloxacin, under the programme.Pre-grant oppositions were filed separately by Sankalp Rehabilitation Trust’s Eldred Tellis and TB survivor Ganesh Acharya, supported by Lawyers’ Collective and Médécins Sans Frontières Access Campaign; and Delhi Network of Positive People, supported by Third World Network.Join conversation InsightfulAgreeDisagreeSkepticalConcerningPromisingWorth ReadingBig Development Patent Controller upheld grounds of lack of novelty, lack of inventive step, non-patentability and insufficient disclosure, refusing application under Sec 15 of Patents Act.

Opponents argued the combination and its use in a shorter regimen had been disclosed in scientific research dating to 2015.The opposition invoked Sections 3(d), 3(e) and 3(i), which restrict patents on new uses of known substances, exclude mere admixtures and methods of medical treatment.

All four grounds were upheld.TB Alliance had earlier licensed generic firms, including Macleods Pharma and Lupin, to manufacture pretomanid for BPaL in India, though health activists called the agreements restrictive. This could widen the supplier pool.

Watch Tuberculosis: What are the causes, symptoms in adults and in children Lower medicine pricesMore generic medicine optionsBetter access to treatmentGovernment support for patients Get the latest India News and Live updates.

Download the TOI app. A business journalist with around two decades of experience tracking key consumer-focussed sectors like consumer durables, retail, consumer goods, aviation, automobiles and advertising, as well as economic ministries of the Union government.

Now, writes primarily on pharmaceuticals and healthcare, and on issues of consumer interest. Besides also looks at trends that are shaping consumer behaviour and the broad consumer landscape. \nYou can follow Rupali on Twitter@Rupalijee.

'I Was Trolled': Ravi Kishan Recalls His Struggles, Urges Youth To Build Skills, Lauds UP’s Growth After Kolkata’s ‘Naked Mob Justice’, Police Parade 3 Accused Semi-Naked To ‘Reconstruct Crime’ 'I Told Saurav...': Ex-SC Judge SK Kaul On Diwali Photo With CJP Leader, Recalls 'Language' Advice Cyclone Arnab Strikes Andhra, Odisha: Seawater Floods Homes, Trees Uprooted, Trains & Flights Hit ‘Not Modi, Shah’s Plaything’: Rahul Gandhi Hits Out, Alleges Tata Is Being ‘Criminally Destroyed’ ‘Forced to Sell Bananas’: CM Yogi Responds After Comedian Harsh Gujral Jokes About UP Crime ‘No Favouritism’: CM Yogi Highlights UP’s Push on Startups, MSMEs & Jobs at TOI Youth Icons Summit Cong Under Fire Over ‘Fake AI Video’ as Army Debunks Chinese Intrusion Claims; Rijiju Hits Out 'We Will Examine': Supreme Court Defers SIR-Form 6 Plea as EC Defends 'Unanimous' Decisions